Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of Glioblastoma

Summary

This will be a prospective, open label, single center, phase I lead-in study of 10 patients to a single arm phase-II study of 37 additional patients to assess the effectiveness of pembrolizumab and lenvatinib combination therapy for recurrent glioblastoma (rGBM) patients wearing TTFields electrodes.

Timeline

Start

2024-06-01

Primary completion

2026-10-01

Completion

2027-10-01

Outcome

Outcome not reported

Stopped: “It was decided by the researcher not to open the study due to administrative issues.”

Drugs

Indications